Bristol-Myers Investors Feel the Harsh Downside of Cancer BetBy
Stock drops 16 percent after Opdivo fails in lung cancer trial
CEO says immunooncology remains ‘central pillar’ of strategy
For almost four years, Bristol-Myers Squibb Co. investors have profited handsomely thanks to the company’s sharp focus on cancer. On Friday, they felt the other side of that concentrated bet.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.